These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35151845)

  • 1. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.
    Wang Y; Wang Y; Ren Y; Zhang Q; Yi P; Cheng C
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):542-565. PubMed ID: 35151845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism.
    Pandey P; Khan F; Upadhyay TK; Maqsood R
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints.
    Xu Y; He L; Fu Q; Hu J
    Front Oncol; 2021; 11():759015. PubMed ID: 34858835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.
    Kouidhi S; Ben Ayed F; Benammar Elgaaied A
    Front Immunol; 2018; 9():353. PubMed ID: 29527212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.
    Meng L; Wu H; Wu J; Ding P; He J; Sang M; Liu L
    Cell Death Dis; 2024 Jan; 15(1):3. PubMed ID: 38177102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
    Shan J; Han D; Shen C; Lei Q; Zhang Y
    Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Breast Cancer Responses to Immunotherapy-a Search for the Achilles Heel of the Tumor Microenvironment.
    Jenkins S; Wesolowski R; Gatti-Mays ME
    Curr Oncol Rep; 2021 Mar; 23(5):55. PubMed ID: 33755828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immunotherapy targets in lung cancer.
    Zhu HH; Feng Y; Hu XS
    Chin Med J (Engl); 2020 Oct; 133(20):2456-2465. PubMed ID: 32947361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment.
    Jiang Z; Hsu JL; Li Y; Hortobagyi GN; Hung MC
    Front Oncol; 2020; 10():1197. PubMed ID: 32775303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.